'Botox index' points to declining cosmeceuticals

Allergan's sales woes are a tipoff to declining sales of cosmetic pharmaceuticals in general: Despite predictions that Botox would be recession-proof, the wrinkle fighter lost 3 percent of its sales in the fourth quarter to come in at $329 million, and the company's dermal fillers saw revenues sink by 8.8 percent to $56 million. Experts predict the trend will apply at other companies, too. Report

Suggested Articles

Mylan and Pfizer's Upjohn have a name for their pending merger: Viatris. Heard that before? So has Mylan, which owns a subsidiary with the same name.

Intercept presented a data analysis that found treatment with Ocaliva led to "early and consistent improvements" in a range of noninvasive tests.

Days before Amarin faces a pivotal FDA vote on its Vascepa expansion, advisors are set to scrutinize the placebo used in its pivotal outcomes trial.